Wir sind mit live! Mehr erfahren
294,66 USD
+1,43
0,49 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
295,00
+0,34
0,12 %
1 Tag
0,49 %
5 Tage
6,26 %
1 Monat
3,48 %
3 Monate
-11,03 %
6 Monate
-12,92 %
Seit Jahresbeginn
-15,37 %
1 Jahr
-20,2 %
5 Jahre
12,44 %
10 Jahre
159,45 %
 

Profil: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.

Mitarbeiter: 56.000

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 39,1 %
Neutral 56,5 %
Negativ 4,3 %
Neutral
GlobeNewsWire
gestern
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) investors concerning the Company's possible violations of the federal securities laws.
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Neutral
PRNewsWire
gestern
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Neutral
GlobeNewsWire
gestern
Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Neutral
GlobeNewsWire
vorgestern
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) on behalf of investors concerning the Company's possible violations of federal securities laws.
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Neutral
PRNewsWire
vorgestern
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Stryker has received FDA 510(k) clearance for Sonopet ® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility.
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Neutral
GlobeNewsWire
vor 3 Tagen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Positiv
Seeking Alpha
vor 3 Tagen
Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story
Stryker rebounded in 2Q26, with operating momentum restored after the prior quarter's cybersecurity disruption. 2Q26 sales rose 9.4% YoY to ~$6.6 billion; organic growth reached ~9%, demonstrating resilience despite earlier headwinds. Adjusted EPS increased ~18% to $3.69, and operating margin expanded 170 bps to 27.4%, reflecting improved profitability.
Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story
Neutral
PRNewsWire
vor 8 Tagen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Neutral
GlobeNewsWire
vor 10 Tagen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Negativ
Investors Business Daily
vor 10 Tagen
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their chief executives would soon step down.
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Kursdiagramme mit Lightweight Charts™ umgesetzt